Form 4: Lifecore Biomedical Executive Stock Withholding

Chief Legal & Administration Officer Thomas D. Salus reported the withholding of 24,645 shares to cover tax obligations.

Summary

• Thomas D. Salus, Chief Legal & Administration Officer of Lifecore Biomedical, Inc. (LFCR), executed a transaction on April 14, 2026.
• The company withheld 24,645 shares of common stock to satisfy tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
• Following this transaction, the reporting person maintains a beneficial ownership of 246,333 shares of common stock.
• The transaction was executed at a price of $5.20 per share.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine administrative action regarding executive tax obligations rather than a discretionary sale of stock.

Positives

• The transaction reflects the vesting of equity compensation, which is a standard component of executive remuneration.

Negatives

• The transaction results in a reduction of the executive's direct shareholding in the company.

Risks

• None identified; this is a routine administrative transaction related to tax compliance.

Future Outlook

No forward-looking guidance or strategic outlook provided in this filing.

Industry Context

StockSavvy.ai notes that this filing is a standard regulatory disclosure for executive compensation and does not indicate a change in corporate strategy or market sentiment.

Comparison to Industry Standards

• The practice of withholding shares to satisfy tax obligations upon RSU vesting is a standard industry practice for publicly traded companies in the United States.

Stakeholder Impact

• Minimal impact on shareholders as the transaction is a standard tax-related equity settlement.

Next Steps

• None

Key Dates

Keywords

Lifecore Biomedical, LFCR, Form 4, Insider Trading, Equity Vesting, Tax Withholding